As GSK weathers the storm of sinking vaccine sales and gears up for key launches in its specialty medicines sector, the ...

GSK plc GSK reported first-quarter 2025 core earnings of $1.13 per American depositary share (ADS), which beat the Zacks ...

British drugmaker GSK insisted it was “well positioned” to respond to the impact of sector-specific tariffs amid widespread ...

GSK is 'well positioned' to deal with the potential implications of any new US tariffs on pharma imports, the group said on ...

Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...

We expect GSK's specialty products like Cabenuva, Juluca, Dovato, Nucala, Ojjaara, Jemperli and Trelegy Ellipta to have driven first-quarter sales performance.

GSK’s blood cancer drug Blenrep won regulatory approval in the U.K., marking the medicine’s return to the market after it was ...

Some justices may be skeptical of a bid by GSK, Pfizer and others to overturn ruling allowing lawsuits to proceed over claims ...

GSK posted adjusted earnings per share of $1.20, surpassing the consensus estimate of $1.02. Revenue for the quarter came in at $10.06 billion, beating expectations of $9.48 billion and representing a ...

The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has authorised GSK’s Blenrep for treating multiple ...